Gapping up
In reaction to strong earnings/guidance:
- SEDG +17.7%, AKRX +16.2%, EVER +10.6%, GWPH +8.4%, ICL +7.4%, DCO +7.1%, MNK +6.8%, ADNT +6.8%, COHU +5.1%, AIG +4.8%, GTE +4.4%, AVID +4.3%, RACE +4.3%, NTEC +4%, ENSG +3.8% (also announces home health, hospice, and senior living spin-off), BLD +3.5%, EGOV +3.3%, USFD +3.3%, ITRI +3.1%, CROX +3.1%, KRG +2.8%, PINC +2.8%, TCMD +2.5%, GLMD +2.4%, SERV +2.3%, CDXS +1.8%, INVH +1.6%, EGRX +1.5%, AIZ +1.4%, LCI +1.3%, FMC +1.3%, BKD +1.2%, HTZ +1.2%, ATKR +1.2%, TGE +1.2%, OMI +1.1%, ABEV +1.1%
Other news:
- OSMT +23.2% (announces 'positive' topline results of its second Phase III efficacy and safety clinical trialof RVL and long-term Phase III safety study for the treatment of ptosis)
- COOP +3% (ticking higher after CFO disclosed the purchase of ~110K shares worth nearly $1 mln)
- MDWD +3% (enters into exclusive license agreement with Vericel (VCEL) for commercial rights to NexoBrid)
- PINC +2.8% (announces exit from specialty pharmacy business; to sell certain assets for $22.5 mln; gives adj. EBITDA guidance)
- FNKO +2% (following exec appearance on MadMoney)
- EGRX +1.5% (announces positive results on study evaluating of neuroprotective effects of RYANODEX secondary to nerve agent exposure)
Analyst comments:
- CHRS +3.5% (initiated with a Buy at H.C. Wainwright)
- DLTH +2.3% (upgraded to Outperform from Neutral at Robert W. Baird)
- VSLR +1.9% (upgraded to Buy from Neutral at Citigroup)
- SBGI +1.7% (upgraded to Outperform from In-line at Evercore ISI)
- PLNT +0.9% (upgraded to Outperform from Neutral at Macquarie)